Groupe d'Etude en Oncologie du Quebec

Titre	Étude Pilote de Phase II Sur l'Effet du méthylphénidate Sur la Fonction Cognitive Des Patientes en rémission d'un Cancer du Sein
Protocole ID	CogMet
ClinicalTrials.gov ID	NCT02970500
Type(s) de cancer	Sein
Phase	Phase II
Type étude	Support
Médicament	Méthylphénidate
Institution	CISSS DE CHAUDIERE-APPALACHES HOTEL-DIEU DE LEVIS 143 rue Wolfe, Lévis, QC, G6V 3Z1
Ville	Beauceville
Investigateur(trice) principal(e)	Dre Anne Dagnault
Coordonnateur(trice)	Pierre Bédard 418-835-7121
Statut	Actif en recrutement
Critètes d'éligibilité	Breast cancer stade I, II or III had received chemotherapy and/or radiotherapy being in remission of her breast cancer complaining of cognitive impairment
Critètes d'exclusion	Current or recent use of psychostimulant drugs Women receiving drugs like: Anticoagulants Antidepressants Drugs (cocaine) Erythropoietin Drugs acting on the cerebral dopaminergic system, including drugs that inhibit monoamine oxidase Currently taking John's wort, natural medicines for depression or supplements for fatigue. Conditions that may increase the risk of cognitive impairment or toxicity of methylphenidate such as : Pregnancy and breastfeeding Migraine, headache Bipolar status Cerebral tumor or any brain injury Metastatic cancer Alcohol addiction Drug Active Major depression Parkinson disease Dementia Epilepsia, Glaucoma Cardiovascular diseases Auto-immunes and chronic inflammatory disease Narcolepsia Pheochromocytome Thyrotoxicosis Motor tic, Gilles de la Tourette syndrome Anxiety

Groupe d'étude en oncologie du Québec